197 related articles for article (PubMed ID: 9730951)
1. GLP-1 action in L6 myotubes is via a receptor different from the pancreatic GLP-1 receptor.
Yang H; Egan JM; Wang Y; Moyes CD; Roth J; Montrose MH; Montrose-Rafizadeh C
Am J Physiol; 1998 Sep; 275(3):C675-83. PubMed ID: 9730951
[TBL] [Abstract][Full Text] [Related]
2. Glucagon-like peptide-1 (GLP-1) and glucose metabolism in human myocytes.
Luque MA; González N; Márquez L; Acitores A; Redondo A; Morales M; Valverde I; Villanueva-Peñacarrillo ML
J Endocrinol; 2002 Jun; 173(3):465-73. PubMed ID: 12065236
[TBL] [Abstract][Full Text] [Related]
3. Dual glucagon recognition by pancreatic beta-cells via glucagon and glucagon-like peptide 1 receptors.
Moens K; Flamez D; Van Schravendijk C; Ling Z; Pipeleers D; Schuit F
Diabetes; 1998 Jan; 47(1):66-72. PubMed ID: 9421376
[TBL] [Abstract][Full Text] [Related]
4. Point mutations in the first and third intracellular loops of the glucagon-like peptide-1 receptor alter intracellular signaling.
Heller RS; Kieffer TJ; Habener JF
Biochem Biophys Res Commun; 1996 Jun; 223(3):624-32. PubMed ID: 8687446
[TBL] [Abstract][Full Text] [Related]
5. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells.
Göke R; Fehmann HC; Linn T; Schmidt H; Krause M; Eng J; Göke B
J Biol Chem; 1993 Sep; 268(26):19650-5. PubMed ID: 8396143
[TBL] [Abstract][Full Text] [Related]
6. Ligand-induced regulation of glucagon-like peptide-I receptor function and expression in insulin-secreting beta cells.
Fehmann HC; Jiang J; Pitt D; Schweinfurth J; Göke B
Pancreas; 1996 Oct; 13(3):273-82. PubMed ID: 8884849
[TBL] [Abstract][Full Text] [Related]
7. Mutations to the third cytoplasmic domain of the glucagon-like peptide 1 (GLP-1) receptor can functionally uncouple GLP-1-stimulated insulin secretion in HIT-T15 cells.
Salapatek AM; MacDonald PE; Gaisano HY; Wheeler MB
Mol Endocrinol; 1999 Aug; 13(8):1305-17. PubMed ID: 10446905
[TBL] [Abstract][Full Text] [Related]
8. Evidence that glucagon stimulates insulin secretion through its own receptor in rats.
Kawai K; Yokota C; Ohashi S; Watanabe Y; Yamashita K
Diabetologia; 1995 Mar; 38(3):274-6. PubMed ID: 7758872
[TBL] [Abstract][Full Text] [Related]
9. Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide.
Kolligs F; Fehmann HC; Göke R; Göke B
Diabetes; 1995 Jan; 44(1):16-9. PubMed ID: 7813808
[TBL] [Abstract][Full Text] [Related]
10. The human glucagon-like peptide-1 (GLP-1) receptor. Cloning and functional expression.
Dillon JS; Wheeler MB; Leng XH; Ligon BB; Boyd AE
Adv Exp Med Biol; 1997; 426():113-9. PubMed ID: 9544263
[No Abstract] [Full Text] [Related]
11. Interaction of glucagon-like peptide-I (GLP-I) and galanin in insulin (beta TC-1)- and somatostatin (RIN T3)-secreting cells and evidence that both peptides have no receptors on glucagon (INR1G9)-secreting cells.
Fehmann HC; Janssen M; Göke B
Acta Diabetol; 1995 Oct; 32(3):176-81. PubMed ID: 8590787
[TBL] [Abstract][Full Text] [Related]
12. Glucagon-like peptide-1 improves insulin and proinsulin binding on RINm5F cells and human monocytes.
Ebinger M; Jehle DR; Fussgaenger RD; Fehmann HC; Jehle PM
Am J Physiol Endocrinol Metab; 2000 Jul; 279(1):E88-94. PubMed ID: 10893327
[TBL] [Abstract][Full Text] [Related]
13. Interaction of GLP-I and leptin at rat pancreatic B-cells: effects on insulin secretion and signal transduction.
Fehmann HC; Bode HP; Ebert T; Karl A; Göke B
Horm Metab Res; 1997 Nov; 29(11):572-6. PubMed ID: 9479558
[TBL] [Abstract][Full Text] [Related]
14. A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells.
Perry T; Lahiri DK; Chen D; Zhou J; Shaw KT; Egan JM; Greig NH
J Pharmacol Exp Ther; 2002 Mar; 300(3):958-66. PubMed ID: 11861804
[TBL] [Abstract][Full Text] [Related]
15. Glucagon-like peptide-1 is a physiological incretin in rat.
Wang Z; Wang RM; Owji AA; Smith DM; Ghatei MA; Bloom SR
J Clin Invest; 1995 Jan; 95(1):417-21. PubMed ID: 7814643
[TBL] [Abstract][Full Text] [Related]
16. Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors.
Holst JJ
Expert Opin Emerg Drugs; 2004 May; 9(1):155-66. PubMed ID: 15155141
[TBL] [Abstract][Full Text] [Related]
17. Identification of glucagon-like peptide-2 (GLP-2)-activated signaling pathways in baby hamster kidney fibroblasts expressing the rat GLP-2 receptor.
Yusta B; Somwar R; Wang F; Munroe D; Grinstein S; Klip A; Drucker DJ
J Biol Chem; 1999 Oct; 274(43):30459-67. PubMed ID: 10521425
[TBL] [Abstract][Full Text] [Related]
18. Effects of the novel (Pro3)GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin.
Gault VA; O'Harte FP; Harriott P; Mooney MH; Green BD; Flatt PR
Diabetologia; 2003 Feb; 46(2):222-30. PubMed ID: 12627321
[TBL] [Abstract][Full Text] [Related]
19. Truncated glucagon-like peptide-1 interacts with exendin receptors on dispersed acini from guinea pig pancreas. Identification of a mammalian analogue of the reptilian peptide exendin-4.
Raufman JP; Singh L; Singh G; Eng J
J Biol Chem; 1992 Oct; 267(30):21432-7. PubMed ID: 1328231
[TBL] [Abstract][Full Text] [Related]
20. Novel signal transduction and peptide specificity of glucagon-like peptide receptor in 3T3-L1 adipocytes.
Montrose-Rafizadeh C; Yang H; Wang Y; Roth J; Montrose MH; Adams LG
J Cell Physiol; 1997 Sep; 172(3):275-83. PubMed ID: 9284947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
